A Pilot, Safety and Feasibility Trial of Anti-Thymocyte Globulin (ATG), Pegylated Granulocyte Colony Stimulating Factor (GCSF), Low Dose Interleukin-2 (IL-2), Etanercept and Exenatide in the Treatment of New Onset Type 1 Diabetes

Trial Profile

A Pilot, Safety and Feasibility Trial of Anti-Thymocyte Globulin (ATG), Pegylated Granulocyte Colony Stimulating Factor (GCSF), Low Dose Interleukin-2 (IL-2), Etanercept and Exenatide in the Treatment of New Onset Type 1 Diabetes

Not yet recruiting
Phase of Trial: Phase I/II

Latest Information Update: 28 Aug 2017

At a glance

  • Drugs Aldesleukin (Primary) ; Antithymocyte globulin (Primary) ; Etanercept (Primary) ; Exenatide (Primary) ; Pegfilgrastim (Primary)
  • Indications Type 1 diabetes mellitus
  • Focus Pharmacodynamics
  • Acronyms DIPIT
  • Most Recent Events

    • 22 Aug 2017 Planned initiation date changed from 1 Aug 2017 to 1 Jan 2018.
    • 10 Jun 2017 Biomarkers information updated
    • 24 Apr 2017 Planned initiation date changed from 1 Jun 2017 to 1 Aug 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top